Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Clinical Study of the Safety and Efficacy of MEBO® Wound Ointment in Subjects With Diabetic Foot Ulcers (Pilot)

This study has been completed.
Information provided by (Responsible Party):
Skingenix, Inc. Identifier:
First received: June 28, 2010
Last updated: July 23, 2013
Last verified: July 2013

The objective of this study is to evaluate the safety and efficacy of MEBO in the treatment of subjects with diabetic foot ulcers (DFUs).

Condition Intervention Phase
Diabetic Foot Ulcers
Drug: MEBO Wound Ointment (MEBO)
Procedure: Standard of Care (sterile saline moistened gauze)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Controlled, Two-Center Pilot Study of the Safety and Efficacy of Topically Applied MEBO® Wound Ointment Compared to Standard of Care in Subjects With Diabetic Foot Ulcers

Resource links provided by NLM:

Further study details as provided by Skingenix, Inc.:

Primary Outcome Measures:
  • The incidence of complete healing of the target ulcer. [ Time Frame: 8 weeks of treatment period ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time required to achieve complete healing (days). [ Time Frame: 8 weeks treatment period ] [ Designated as safety issue: No ]
  • Absolute and percentage change in ulcer surface area from baseline to endpoint. [ Time Frame: 8 weeks treatment period ] [ Designated as safety issue: No ]

Enrollment: 7
Study Start Date: November 2010
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MEBO Wound Ointment (MEBO)
Topical application twice a day
Drug: MEBO Wound Ointment (MEBO)
Topical application twice a day
Active Comparator: Standard of Care (sterile saline moistened gauze)
Topical application twice a day
Procedure: Standard of Care (sterile saline moistened gauze)

Detailed Description:

This is a phase II, randomized, controlled, two-center pilot study designed to assess the safety and efficacy of MEBO in the treatment of subjects with DFUs. Subjects meeting entry criteria will be randomly assigned in a 1:1 ratio for up to 8 weeks of treatment with either MEBO or SOC.


Ages Eligible for Study:   18 Years to 79 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female ≥18 years of age
  • Able and willing to provide informed consent
  • Able and willing to comply with protocol visits and procedures
  • Target ulcer duration of ≥4 weeks

Exclusion Criteria:

  • Ulcer of a non-diabetic pathophysiology
  • Known or suspected allergies to any of the components of MEBO
  • Malignancy on target ulcer foot
  • Non-compliance in the screening or run-in period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01154374

United States, Connecticut
Blume Podiatry Group, P.C.
New Haven, Connecticut, United States, 06515
United States, Massachusetts
Boston University School of Medicine
Boston, Massachusetts, United States, 02118
Sponsors and Collaborators
Skingenix, Inc.
Study Chair: Robert S Kirsner, MD, PhD University of Miami
  More Information

No publications provided

Responsible Party: Skingenix, Inc. Identifier: NCT01154374     History of Changes
Other Study ID Numbers: MEBO-DFU-PILOTII-001
Study First Received: June 28, 2010
Last Updated: July 23, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Skingenix, Inc.:
Diabetic Foot Ulcers (DFUs)

Additional relevant MeSH terms:
Diabetic Foot
Foot Ulcer
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Diabetic Angiopathies
Diabetic Neuropathies
Endocrine System Diseases
Foot Diseases
Leg Ulcer
Pathologic Processes
Skin Diseases
Skin Ulcer
Vascular Diseases processed this record on March 02, 2015